Infection Control Market

Infection Control Market Analysis

The infection control market stands at USD 102.36 billion in 2025 and is forecast to reach USD 139.94 billion by 2030, growing at a 6.45% CAGR. Rising reimbursement penalties tied to hospital-acquired infections (HAIs), rapid hospital adoption of low-temperature sterilizers, and sustained demand for single-use protective products underpin this growth. Healthcare providers are reallocating capital toward advanced sterilization platforms as the EPA tightens ethylene oxide (EtO) emission limits. Artificial-intelligence surveillance systems further accelerate preventive strategies by predicting infection clusters in real time, while contract sterilization outsourcing expands because specialist operators can amortize new compliance costs across multiple clients. Asia-Pacific, supported by the ongoing scale-up of Chinese healthcare spending, contributes the largest incremental revenue through 2030.

Global Infection Control Market Trends and Insights

Stringent Global HAI-Reduction Targets & Reimbursement Penalties

CMS value-based purchasing now links reimbursements to infection metrics, including catheter-associated urinary tract infections and central line-associated bloodstream infections. California and other states mirror these incentives, prompting hospital boards to budget for new sterilizers and data-analytics tools. Facilities that fell short during the COVID-19 disruption report a renewed focus on policy-compliant equipment upgrades. Medium-term pressure remains elevated as the Transforming Episode Accountability Model begins in 2026, making infection control performance essential for revenue integrity.

Procedure Volume Surge From Chronic & Geriatric Disease Burden

Inpatient discharges are projected to climb to 31 million while outpatient volumes rise to 5.82 billion procedures by 2034. Orthopedic, spine, and gastroenterology procedures increasingly migrate to ambulatory centers, requiring advanced sterilizers capable of rapid cycles. China’s pathway toward RMB 205 trillion in health outlays by 2030 mirrors this structural procedure expansion. Longer life expectancy and multimorbidity raise infection risk, reinforcing the commercial case for predictive surveillance platforms that identify high-risk patients pre-operatively.

Outsourcing Boom in Contract Sterilization Services

Sterigenics alone manages 48 sites across 13 countries, serving more than 2,000 clients. New EtO ventilation and monitoring rules cost facilities up to USD 900 million; outsourcing enables hospitals to avoid these capital charges while securing regulatory expertise. Specialist providers adopt vaporized hydrogen peroxide lines approved by the FDA, tempering EtO reliance and shortening turnover times. Small facilities leverage these partnerships to keep surgical blocks open without major capital allocations.

Rapid Adoption of Low-Temperature & Plasma Sterilizers

Hydrogen-peroxide gas-plasma cycles sterilize 95% of test materials in 75 minutes and leave no toxic residue. STERIS and ASP earned clearances for complex duodenoscope processing, pushing uptake in high-risk endoscopy suites. Electromagnetic-seal containers and cold plasma units extend sterilization to heat-sensitive instruments, lowering device repair costs while reducing surgical-site infections.

Safety & Liability Concerns Around Reprocessed Instruments

Complex lumened devices are prone to incomplete decontamination, raising malpractice exposure. Multidrug-resistant Klebsiella strains with biocide tolerance have already surfaced in hospital outbreaks. Updated ANSI/AAMI ST24 guidance demands rigorous performance validation, yet many facilities delay upgrades for budget reasons, sustaining litigation risk.

Capital-Intensive Nature of Advanced Sterilization Equipment

Compliance with the revised EtO rule costs smaller hospitals millions, diverting funds from other patient-care technologies. Low-temperature units require separate HVAC loops, advanced monitoring, and specialized staff training, stretching payback periods beyond traditional board approval thresholds—particularly in volatile emerging-market currencies.

Segment Analysis

By Products & Services: Sterilization Dominance Drives Technology Innovation

Sterilization products and services controlled 42.74% infection control market share in 2024. Heat sterilizers continue to anchor budgets because of entrenched staff familiarity, yet low-temperature hydrogen-peroxide plasma units are posting double-digit placement growth within tertiary centers. The infection control market size for this segment is forecast to reach USD 59.8 billion by 2030, advancing at a pace aligned with overall industry CAGR. Contract sterilization providers, leveraging scale, invest in multi-modal processing lines that individual hospitals struggle to fund. Protective barriers, the fastest-growing area, increasingly incorporate compostable substrates to satisfy ESG audits, even as hospitals audit glove and gown burn rates to ensure pandemic-era stockpiles remain current.

Cleaning chemicals face potent headwinds from antimicrobial resistance. Laboratories confirm that 80% of multidrug-resistant Pseudomonas isolates defeat standard QAC solutions, prompting formulators to explore quaternary phosphonium molecules with broader kill spectrums. Automated endoscope reprocessors with leak-testing and traceability modules are gaining mindshare because manual flushing cannot consistently navigate intricate device channels. Overall, product strategists are prioritizing sterilization throughput, eco-toxicity, and real-time compliance analytics.

By Service Delivery Mode: Contract Services Gain Momentum

Hospitals retained 54.13% control over infection-control tasks in 2024, yet rising environmental and worker-safety rules accelerate the shift toward outsourcing. The infection control market size for contract services is projected to post a 6.88% CAGR to 2030 as provider networks weigh total cost of ownership against outsourcing fees. Centralized vendors distribute EtO and vaporized hydrogen peroxide capacity across multisite networks, offering surge coverage when in-house units undergo maintenance. Third-party operators also manage record-keeping and validation, limiting liability under CMS audits.

In urgent-care chains and ambulatory centers, contract partners deliver pick-up and return cycles aligned to procedural scheduling, removing the need for on-site sterilization bays that consume scarce square footage. In Asia-Pacific, capacity additions cluster around export-oriented device manufacturers, creating dual revenue streams from hospital instruments and original-equipment processing.

By End-User: ASCs Drive Outpatient Infection Control Growth

Hospitals and clinics represented 38.34% infection control market revenue in 2024, yet ambulatory surgery centers posted the strongest trajectory at a 7.01% CAGR. Infection control market size for ASCs is expected to touch USD 12.4 billion by 2030 as orthopedics, ENT, and gastroenterology cases migrate from inpatient wings. ASC executives prioritize compact low-temperature cabinets that achieve 60-minute room turnaround, sustaining high case volumes.

Medical-device firms depend on contract sterilizers for product throughput, with EtO services covering roughly half of all device SKUs. Pharmaceutical plants under EU GMP Annex 1 now feature integrated vaporized hydrogen peroxide tunnels to validate fill-finish lines. Veterinary clinics and research labs round out secondary demand, seeking miniaturized plasma units suited to lower instrument loads without compromising sterility assurance levels.

Geography Analysis

North America accounted for 39.34% infection control market revenue in 2024. The region adopts innovations early, spurred by CMS reimbursement structures and a dense network of ASC facilities needing fast sterilizer cycles. U.S. policy shifts, such as the FY 2025 IPPS rule, embed infection metrics into broader quality reporting, intensifying hospital spending on predictive analytics platforms.

Europe follows closely, guided by medical-device directives that integrate carbon-footprint scoring into product approvals. Hospitals weigh reusable barrier programs against infection risk, leading to pilot projects pairing reusable gowns with plasma sterilization cabinets to maintain efficacy. Infection control market size in Europe is expected to approach USD 37 billion by 2030.

Asia-Pacific delivers the fastest 7.12% CAGR. China’s pathway toward RMB 205 trillion in health spending drives new hospital construction and bulk procurement of EtO and hydrogen-peroxide lines. India’s National Quality Assurance Standards now mandate central sterile services departments in district hospitals, stimulating equipment tenders. Japan’s aging population pushes device reprocessing volumes, while South-East Asian private hospital chains outsource sterilization to regional hubs.

The Middle East and Africa invest in flagship medical cities with central sterile processing designed to Joint Commission standards, though fragmented smaller clinics still rely on tabletop autoclaves. In South America, public-sector infection-control budgets grow alongside universal-health-coverage rollouts, creating mixed demand for premium and mid-tier equipment.

Competitive Landscape

Industry concentration is moderate. Ecolab divested its surgical-solutions unit to Medline for USD 950 million in 2024, showing portfolio refocus toward core chemistry platforms^{[1]Health Exec, “Ecolab Sells Surgical Solutions Unit,” healthexec.com}. 3M’s healthcare spinoff, Solventum, is now an USD 8.2 billion infection-control pure-play, enabling targeted R&D on low-temperature sterilization catalysts^{[2]3M, “Completion of Solventum Spin-Off,” news.3m.com}.

Metall Zug and Miele merged Belimed and Steelco into a EUR 423 million joint venture, pooling engineering resources across washer-disinfectors and steam sterilizers^{[3]Metall Zug AG, “Steelco-Belimed Joint Venture Announcement,” metallzug.ch}.

Technology differentiation now leans on real-time analytics and eco-friendly sterilants. Solventum’s 2025 launch of a pre-assembled vaporized hydrogen-peroxide test pack simplifies routine biological monitoring, cutting technician labor. STERIS pilots plasma chambers with integrated AI dashboards that auto-adjust dwell times based on load geometry. Start-ups exploit white space in UV-C and cold-plasma disinfection, targeting rapid device turnarounds without chemical residues.